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ABSTRACT 
Objective: The first aim of this study was to determine the prevalence of childhood and current 
attention deficit hyperactivity disorder (ADHD) symptoms in patients with fibromyalgia. The 
second aim is to assess the role of depression and anxiety on the relationship between childhood 
and adult ADHD symptoms with disease impact in this population. 
Methods: 64 patients with fibromyalgia were compared to matched 58 healthy controls. All 
participants completed the Wender Utah Rating Scale (WURS), Adult ADHD Self-Report 
Scale (ASRS), Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI) and 
Fibromyalgia Impact Questionnaire (FIQ).  
Results: Patients with fibromyalgia had significantly higher mean scores of depression (BDI), 
anxiety (BAI), childhood ADHD symptoms (WURS), and adult ADHD symptoms (ASRS total, 
ASRS hyperactivity/impulsivity subscale and ASRS attention deficit subscale) than the control 
group. Fibromyalgia impact (FIQ) was significantly correlated with depression (BDI) (r=0.57, 
p<.001), anxiety (BAI) (r=0.56, p<.001) and childhood ADHD symptoms (WURS) (r=0.41, 
p<.001) in fibromyalgia group. There was no significant correlation between fibromyalgia 
impact (FIQ) and adult ADHD symptoms (ASRS total or sub-scale scores). Hierarchical 
multiple regression indicated that childhood ADHD symptoms (WURS), anxiety (BAI) and 
depression (BDI) predicted fibromyalgia impact. Both anxiety (BAI) and depression (BDI) 
mediated the relationship between childhood ADHD symptoms (WURS) and fibromyalgia 
impact (FIQ). 
Conclusion: Childhood ADHD symptoms may be a contributory factor to poorer functioning 
in the patients with fibromyalgia. The relationship was more pronounced in the presence of 
depression and anxiety symptoms. Evaluation of childhood and adult ADHD symptoms in 
patients with fibromyalgia is important for recognition and treatment of ADHD comorbidity 
and also for attenuating the severity of the disease. 
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Fibromyalgia (FM) is an extra-articular rheumatic disease characterized by widespread 
musculoskeletal pain (Wolfe et al., 2010). Fatigue, sleep disturbance, cognitive impairment, 
depressive mood and medically unexplained physical symptoms are common in fibromyalgia 
(Geisser et al., 2008; Rutledge, Mouttapa, & Wood, 2008). Prevalence in the general population 
varies between 2.9% and 4.7%, predominantly affecting female gender (Branco et al., 2010). 
Cognitive complaints are seen approximately in 70% of patients with fibromyalgia and 
contribute to disability related to disease (Katz, Heard, Mills, & Leavitt, 2004). In addition to 
subjective complaints, objective reports of cognitive impairment detected by 
neuropsychological tests were reported, including executive functions, attention, working, 
semantic and episodic memory (Mease et al., 2009; Montoro, Duschek, Muñoz Ladrón de 
Guevara, Fernández-Serrano, & Reyes del Paso, 2015). It has been suggested that distraction is 
the most significantly deteriorated cognitive impairment domain in fibromyalgia and is a 
predictive factor for impaired memory function (Leavitt, & Katz, 2006). Reduced vigilance and 
attention deficit in fibromyalgia patients have also been reported to be associated with 
emotional distress, sleep dysfunction and pain intensity (Miró, Martínez, Sánchez, Prados, & 
Lupiáñez, 2015). 
In addition to cognitive symptoms, the frequency of lifetime and current psychiatric 
comorbidities, mainly mood disorders and anxiety disorders, are relatively high in patients with 
fibromyalgia (Gunduz et al., 2018). The lifetime prevalence of mood disorders was found to be 
between 65-70%, the frequency of anxiety disorder to be 35-68% and the rate of any psychiatric 
disorder was reported to be 81%. Presence of both psychiatric comorbidities and psychiatric 
symptoms negatively affect pain and quality of life in patients with fibromyalgia (Arnold et al., 
2004; Lichtenstein, Tiosano, & Amital, 2018). Besides the similarities in pathophysiology, due 
to common clinical characteristics such as increased frequency of depressive symptoms, 
elevated risk for psychiatric comorbidity and good response to antidepressant therapy; it has 
been suggested that fibromyalgia should be included in the category of affective spectrum 
disorders along with some other psychiatric disorders including attention deficit hyperactivity 
disorder (ADHD) (Gardner, & Boles, 2011). 
There has been an increased interest in ADHD symptoms and ADHD comorbidity in patients 
with fibromyalgia. In an earlier small study, patients with fibromyalgia were reported to have 
higher rates of ADHD symptoms both in adulthood and in childhood when compared to other 
pain disorder groups (Krause, Krause, Magyarosy, Ernst, & Pongratz, 1998). In a recent study, 
possible diagnosis of ADHD assessed by Adult ADHD Self-Report Scale in patients with 
fibromyalgia was more prevalent than the control group and possible ADHD comorbidity was 
shown to have a significant impact on disease severity (Van Rensburg, Meyer, Hitchcock, & 
Schuler, 2017). Childhood ADHD symptoms were also found to be more common in patients 
with fibromyalgia than healthy controls (Reyero et al., 2011). Moreover, the rate of diagnosis 
of fibromyalgia is higher in ADHD patients with cognitive complaints, when compared to 
control groups (Golimstok, Fernandez, & Garcia Basalo, 2015). A recent study conducted in 
Turkey reported ADHD comorbidity for one-third of patients with fibromyalgia (Yılmaz, & 
Tamam, 2018). The reports on the clinical and phenomenological features suggest that there 
may be shared pathophysiological mechanisms of fibromyalgia and ADHD. Some authors 
suggested a common mechanism of cognitive impairment associated with dysfunction of 
dopaminergic pathways in fibromyalgia and ADHD (Arnsten, 2006; Kravitz, & Katz, 2015).  
Despite the overlap in clinical features, the current literature on the effect of childhood and 
current ADHD symptoms on the severity of disease in fibromyalgia is very limited. To our 
knowledge, there is no study investigating the moderating role of depression and anxiety 
symptoms on the relationship between childhood and adulthood ADHD symptoms and severity 
of illness in patients with fibromyalgia. The current study sought to meet these shortcomings in 
the literature and expand the available knowledge on the areas of research regarding ADHD 
symptom comorbidity in fibromyalgia and possible factors affecting this relationship which 
may affect the clinical manifestations and impact of fibromyalgia. A better understanding of 
the link between ADHD symptoms and fibromyalgia is important for the need to recognize and 
offer better treatments that will eventually help improve the course of disease. 
In this study we evaluated differences in frequency of childhood and current ADHD symptoms 
between patients with fibromyalgia and a healthy control group, and assess association of these 
symptoms with disease impact in patients with fibromyalgia. We also evaluated the mediating 
roles of depression and anxiety in the relationship between childhood and current ADHD 
symptoms in patients with fibromyalgia. In accordance with the studies reviewed above we 
hypothesized that: (1) Fibromyalgia group would exhibit higher levels of childhood and adult 
ADHD symptoms compared to healthy participants; (2) high childhood and adult ADHD 
symptoms would be associated with more severe anxiety and depression and a greater impact 
of illness (as measured by FIQ); (3) both depression and anxiety would have mediator effects 
on the relationship between ADHD symptoms and disease impact. We considered that the 
disability and clinical manifestations associated with FMS may have a greater effect on 
depression and anxiety, therefore ADHD symptoms. Further analyses were conducted to assess 
the relative magnitude of associations of childhood and adult ADHD symptoms with depression 
and anxiety in each group.  
Methods 
Participants  
72 female patients with fibromyalgia were recruited consecutively from the pain section of 
physical medicine and rehabilitation unit in Bagcilar Training and Research Hospital in 
Istanbul/Turkey between July 2017 and September 2017. The procedure was in line with 
Helsinki Declaration and the study was approved by the local ethics committee of Bagcilar 
Training and Research Hospital. Written and oral informed consents were obtained from the 
patients and control subjects. Data collection and assessment procedures were both conducted 
blindly, groups were randomly assigned. The diagnosis of fibromyalgia was given by physical 
examination and investigation based on the 2010 criteria of the American College of 
Rheumatology (ACR) (Wolfe et al., 2010). These criteria were a) a widespread pain index 
(WPI) ≥7 and symptom severity (SS) scale score of ≥5; or WPI of 3–6 and SS scale score of 
>9; b) the symptoms should be present at a similar level for at least three months; and c) another 
disorder that would otherwise explain the pain should be excluded. All patients were screened 
by the same clinician, who has extensive experience in managing patients with FM and other 
chronic pain disorders. Participants were invited to complete questionnaires after they 
consented the study. Exclusionary criteria were being under 18 years of age, illiterate, having 
severe hearing or vision impairment, clinical diagnoses of intellectual disability, psychotic 
disorder or dementia according to medical records or clinical history. Overall 64 patients were 
included to statistical analysis due to 8 participants with missing data. 58 healthy volunteers 
with matched sociodemographic characteristics were recruited. The healthy control group was 
composed of the hospital workers and patients’ relatives. In addition to not having any kind of 
pain disorder, the control group was subject to the same exclusionary criteria as for the patients. 
Measures 
Wender Utah Rating Scale (WURS) 
The Wender Utah Rating Scale (WURS) is a 61-item self-report assessment scale for ADHD, 
in which the adult patient recalls his or her childhood behaviour. Items fall into three factors; 
dysthymia, oppositional-defiant behaviour and school/work problems. 5 possible responses are 
scored from 0 to 4 points. Those above the cut-off value of 46 points are retrospectively 
diagnosed with ADHD in childhood (Ward, Wender, & Reimherr, 1993). The Turkish validity 
and reliability study of the scale was performed by Oncu, Olmez, and Senturk (2005). 
Cronbach’s alpha coefficients were 0.90 and 0.93 for original and translated versions. 
Adult ADHD Self-Report Scale (ASRS) 
Adult ADHD Self-Report Scale (ASRS) is a screening tool for ADHD developed by the World 
Health Organization (Kessler et al., 2005). Two subscales assessing “attention deficit” and 
“hyperactivity” consist of 9 items each. The questions aim to determine how often each 
symptom occurs within the last six months and the answers are scored between 0-4 points. 
Those who score more than 24 points on any of the two subscales are considered to fall in the 
category "highly likelihood of ADHD", those with 17-23 points are "likely ADHD" and those 
who score 0-16 are not considered as a candidate for ADHD. The Turkish validity and reliability 
study of the scale was performed by Dogan, Oncu, Varol-Saracoglu and Kucukgoncu (2009). 
Cronbach’s alpha coefficients were 0.70 and 0.88 for original and translated versions. 
Beck Depression Inventory (BDI) 
The Beck Depression Inventory (BDI) was developed in 1961 by Beck et al. and composed of 
21 questions or items, each with four possible responses (Beck, Steer, & Carbin, 1988). Each 
response is assigned a score ranging from zero to three, indicating the severity of the symptom. 
Individual questions of the BDI assess mood, pessimism, sense of failure, self-dissatisfaction, 
guilt, punishment, self-dislike, self-accusation, suicidal ideas, crying, irritability, social 
withdrawal, body image, work difficulties, insomnia, fatigue, appetite, weight loss, bodily 
preoccupation, and loss of libido. Items 1 to 13 assess symptoms that are psychological in 
nature, while items 14 to 21 assess more physical symptoms. It was translated into Turkish and 
its reliability was recalculated Hisli for the Turkish population (1988). Cronbach’s alpha 
coefficients were 0.93 and 0.80 for original and translated versions. 
Beck Anxiety Inventory (BAI) 
The Beck Anxiety Inventory (BAI) consists of 21 self-report items with a Likert scale ranging 
from total scores of 0 to 63. It was developed in 1988 and a revised manual was published in 
1993 with changes in scoring (Beck, Epstein, Brown, & Steer, 1988). The scores correlate with 
the level of anxiety and are classified as minimal anxiety (0 to 7), mild anxiety (8 to 15), 
moderate anxiety (16 to 25), and severe anxiety (30 to 63). The Turkish validity and reliability 
study of the scale was conducted by Ulusoy, Hisli and Erkmen (1998). Cronbach’s alpha 
coefficients were 0.92 and 0.93 for original and translated versions. 
Fibromyalgia Impact Questionnaire (FIQ) 
The Fibromyalgia Impact Questionnaire (FIQ) was developed in 1991 by Burckhardt et al. to 
assess a spectrum of problems related to fibromyalgia and associated variables of outcome 
(Burckhardt, Clark, Bennett, 1991). It is composed of self-administered ten items which 
measure physical functioning, work status, depression, anxiety, sleep, pain, stiffness, fatigue 
and wellbeing. The first item consists of ten sub-items and are rated on a 4 point Likert type 
scale and scores on each question can range from 0 (always) to 3 (never). The final scores for 
each item of the FIQ should range from 0 (no impairment) to 10 (maximum impairment) and 
the total maximum score is 100, which represents the maximum impact of disease. The FIQ 
was modified in both 1997 and 2002, however the Turkish validity and reliability study 
conducted by Sarmer, Ergin and Yavuzer (2000) covered the original version, hence utilized in 
this study. Cronbach’s alpha coefficients were 0.95 and 0.72 for original and translated 
versions. 
Statistical Analysis 
Statistical analysis was performed using the software programme SPSS for Windows version 
23.0. Prior to test differences between groups and model tests, assumptions of normal 
distribution of variables were tested by Kolmogorov-Smirnov test. Demographical 
characteristics of the study groups were compared with Chi-square analyses on categorical data 
and Student t test on the continuous variables. Total scores of the clinical scales and subscales 
(BDI, BAI, WURS, ASRS) were compared with multivariate analysis of variance (MANOVA). 
Partial squared eta (h2) was used as effect size indicator. Pearson correlation analysis was used 
to investigate the relationship between measurement variables in the fibromyalgia and control 
groups. Group difference in correlation coefficients were tested with Fisher’s Z statistics. By 
taking FIQ score as dependent variable, hierarchical regression analysis was performed to 
determine the predictors of FIQ score in patients with fibromyalgia. In order to determine the 
effect of the WURS mean score on FIQ score was included in the first block, ASRS score in 
the second block, BAI score in the third block and BDI score in the fourth block of regression 
analysis. Significance level was set at 0.05.  
 
Results 
Comparison of demographic and clinical variables between groups 
The mean ages of the groups were 39.75±10.33 for the patient group and 39.6±8.75 for the 
control group (t=0.224, p=0.823). There was no significant difference between patients with 
fibromyalgia and healthy controls in demographic characteristics (Table 1). Compared to the 
control group, patients with fibromyalgia reported significantly higher scores on clinical scales 
and subscales (Table 2). According to Chi-Square Test results, FM patients were more likely to 
have moderate to severe scores (14-63) in BDI (71.88%) than control group (12.07%). FM 
patients were more likely to have moderate scores (16-25) in BAI (17.19%) and high scores 
(26-63) in BAI (48.44%) than the control group (15.52%, 0.00%, respectively) (Table 3). 
Results of correlation analysis between clinical variables 
Correlation analyses of clinical scales in both FM patients and the control group, as well as 
comparisons of correlation coefficients between groups were reported on Table 4. In the FM 
group, analyses showed significant correlations between all clinical scales, except between FIQ 
scores and ASRS scores. In the control group, all clinical scale and subscale scores were found 
to be correlated between each other. There were no significant differences on correlation 
coefficients between the groups (Table 4). 
Association of childhood ADHD symptoms, anxiety and depression with impact of disease 
A hierarchical multiple regression was implemented to predict impact of disease (FIQ) on 
childhood attention deficit hyperactivity disorder symptoms (WURS), anxiety (BAI) and 
depression (BDI) in the fibromyalgia group. The regression model summary is shown in Table 
5. The hierarchical multiple regression revealed that childhood attention deficit hyperactivity 
disorder (WURS) contributed significantly to the regression model, (F(1,62) = 12.203, p < .01) 
and (R2 = .16). The second model found that anxiety (BAI) (β = .48, p < .001) also contributed 
significantly to the regression model. In addition, when anxiety (BAI) was included in the 
model the main effect of childhood attention deficit hyperactivity disorder (WURS) on 
fibromyalgia syndrome (FIQ) disappeared. In the third model with the addition of depression 
(BDI), it was found that depression (BDI) (β = .52, p < .001) contributed significantly to the 
regression model. in the third model, the main effect of childhood attention deficit hyperactivity 
disorder (WURS) on FIQ was non-significant. 
Discussion 
In this case-control study, both childhood ADHD and adulthood ADHD symptoms were found 
to be more prevalent in patients with fibromyalgia than the control group. ADHD symptoms in 
childhood were associated with disease impact in these adult patients with fibromyalgia, 
however adult ADHD symptoms were not found to be associated with disease severity. We also 
found that both depression and anxiety mediated the relationship between childhood ADHD 
symptoms and disease impact in fibromyalgia group. To our knowledge, this is the first study 
that examines the association of childhood ADHD symptoms with disease impact and 
investigates the role of depression and anxiety in this association in fibromyalgia. 
As expected, FM patients exhibited greater levels of childhood and adult ADHD symptoms 
compared with healthy controls. Higher incidence of both childhood and adult ADHD 
symptoms in patients with fibromyalgia in this study is in line with previous data (Golimstok, 
Fernandez, & Garcia Basalo, 2015; Reyero et al., 2011; Van Rensburg, Meyer, Hitchcock, & 
Schuler, 2017). A recent study demonstrates this symptom-based comorbidity at the clinical 
level as well (Yılmaz, & Tamam, 2018). Cognitive symptoms, emotion regulation problems 
and disturbances in dopaminergic pathways in the central nervous system have been suggested 
as indicators of potential pathophysiological mechanisms of fibromyalgia and ADHD (Bou 
Khalil, Khoury, & Richa, 2018). Patients with FM often report cognitive problems in memory, 
concentration or planning (Kratz et al. 2019). The problems are sometimes referred as fibrofog, 
similar to mental fog that is often described by patients with depression. Cognitive problems 
may partly be contributing the high ADHD symptom scores in our sample.  
Regarding the relationship of childhood and adult ADHD symptoms with depression and 
anxiety in FM patients, our initial hypotheses were confirmed. On the other hand, magnitude 
of the correlations of these variables did not differ between FM and healthy group. Intuitively, 
one would expect stronger correlation with depression and anxiety in FM group but our analyses 
showed it was not the case in our sample. The lack of difference in magnitudes may be related 
to the additional role of ADHD symptoms in emotion regulation. In developmental perspective, 
emotion regulation is a key component in response to ADHD symptoms that leads to 
vulnerability for depression and anxiety (Christiansen, Hirsch, Albrecht, & Chavanon, 2019). 
Emotion regulation is also a major aspect of coping with pain. In our sample, ADHD symptoms 
may have led to dysfunctional coping mechanisms and contributed to depression and anxiety 
in FM patients. (Agar‐Wilson, & Jackson, 2012).  
Our findings suggesting a link between childhood ADHD symptoms and FM moderated by 
depression is in line with a possible shared mechanism that may have an impact on quality of 
life in patients with FM. Future studies will need to address the link between ADHD symptoms 
and objective and subjective cognitive functions in this clinical group. Although our study 
supports the suggestion of common pathophysiology, it has also demonstrated the effect of 
childhood ADHD symptoms on disease impact in patients with fibromyalgia. When examining 
childhood ADHD, somatosensory dysfunction is an entity encountered along the disease course 
(Scherder, Rommelse, Bröring, Faraone, & Sergeant, 2008). Dysfunction in pain processing in 
children with ADHD may lead to a tendency towards or exacerbation of fibromyalgia 
symptoms in adulthood. Additionally, ADHD symptoms in childhood may augment the impact 
of pain in the following years by intensifying the experience of pain due to difficulty in 
regulating emotional experience (Koechlin, Coakley, Schechter, Werner, & Kossowsky, 2018; 
Steinberg, & Drabick, 2015). People with early life adversities show altered pain processing 
and are at increased risk of developing ADHD (Ackerman et al. 1998). Depression and anxiety 
symptoms in FM patients were associated with a history of childhood traumatic events. Bou 
Khalil et al. (2018) suggested that early life adversities may be linked to emotional 
dysregulation that can lead to an overlap syndrome between fibromyalgia and ADHD. 
According to this model, increased negative biases, disinhibition, and distractibility present as 
clinical features in FM and ADHD. In our findings, the mediating role of depression and anxiety 
symptoms can be explained as part of a possible overlap syndrome. That is, shared features of 
emotional dysregulation (including anxiety and depression) between ADHD and FM may play 
role in pathophysiology of both conditions. 
Both anxiety and depression are well known factors to increase risk for pain and disability in 
fibromyalgia, furthermore similar findings in this study support the current literature. In patients 
with fibromyalgia, depressive disorder is the most frequent comorbid psychiatric condition with 
prevalence figures up to 20-80% (Fietta, 2007). Previous research indicated that depressive 
symptoms without a formal diagnosis of depressive disorder often accompany fibromyalgia 
(Kato, Sullivan, Evengård, Pedersen, 2006). When accompanied by depression, patients with 
fibromyalgia are observed to report somatic symptoms and pain more commonly (Thieme, 
Turk, & Flor, 2004). An asserted mechanism on how depression exacerbates pain in 
fibromyalgia is the pain inhibition hypothesis (de Souza, Potvin, Goffaux, Charest, & 
Marchand, 2009). Similarly, although the incidence of anxiety disorders in patients with 
fibromyalgia is quite high when compared to those without anxiety, the association of anxiety 
levels and anxiety disorders with the severity of pain in fibromyalgia and the effect of disease 
is relatively less clear (Raphael, Janal, Nayak, Schwartz, & Gallagher, 2006). Patients with 
fibromyalgia accompanied by anxiety reported more somatic complaints and more tender point 
sum scores were found in these individuals than those without anxiety disorders (Thieme, Turk, 
& Flor, 2004). In line with the current literature, our study showed the negative effect of high 
levels of anxiety on fibromyalgia impact. The physiological reaction accompanying anxiety 
might be the underlying cause to decrease pain threshold and increase the soreness of pain in 
these patients (Schmidt, & Cook, 1999). In addition, depression and anxiety may increase the 
severity of the disease by means of affecting pain modulation through neurobiological 
mechanisms in which neurotransmitters such as serotonin and noradrenaline are involved 
(Blackburn-Munro, & Blackburn-Munro, 2001; Porro, 2003). 
In our study, ADHD symptoms measured by ASRS were not associated with pain and disability 
in fibromyalgia, in contrast to the findings of van Rensburg et al. (2017). The regression 
analyses revealed that the impact of childhood ADHD symptoms on fibromyalgia was mediated 
by depression and anxiety. Longitudinal follow-up studies examining ADHD have found that 
depressive and anxiety disorders are highly associated with ADHD symptoms occurring in the 
childhood (Uchida, Spencer, Faraone, & Biederman, 2018). Similarly, both depression and 
dysthymia are often seen together with adult ADHD, with incidence of depressive disorder as 
18.6-53.3% (Kessler et al., 2006; Torgersen, Gjervan, & Rasmussen, 2006). Furthermore, 
ADHD comorbidity in individuals with depressive disorder varies between 9% and 16% 
(McIntosh et al., 2009). Anxiety disorder is another common comorbidity in individuals with 
ADHD. The diagnosis of ADHD is often delayed in the context of comorbid anxiety when the 
symptoms complicate the clinical picture, possibly due to inhibition of impulsivity when feeling 
on the edge (Schatz, & Rostain, 2006). In a recent study, 28% of the individuals referred to a 
tertiary clinic for mood and anxiety assessment have been reported to manifest clinically 
undetected ADHD (Sternat, Mohamed, & Furtado, 2016). Emotion regulation problems in the 
children with ADHD may be the underlying condition for the development of depression and 
anxiety symptoms in their later life (Steinberg, & Drabick, 2015). 
One of the main limitations of our study was the retrospective assessment of childhood ADHD 
symptoms along with self-report basis scale measurement of current adulthood ADHD 
symptoms lacking clinical interview (psychiatric evaluation). It should be noted that ADHD 
symptoms in the adulthood can easily be confused with many other psychiatric disorder 
symptoms. Therefore, it is difficult to determine whether the symptoms of attention deficit 
observed in fibromyalgia are specific to fibromyalgia or are a manifestation of ADHD itself. 
Due to the cross-sectional nature of our study, the impact of confounding factors may have been 
more pronounced. In this study, it was not possible to rule out possible confounding factors 
such as medication use, sleeping habits, eating behaviour, or physical exercise as the data on 
those measures were not collected. Longitudinal studies are required to investigate the role of 
confounders more clearly. Using standardised clinical interviews will help ruling out the 
confounding effect of personality traits or bipolar disorder. Unfortunately, it is not possible to 
determine whether childhood ADHD symptoms lead to depressive symptoms in later life and 
therefore aggravation of pain in patients with fibromyalgia because of the design of the study. 
Also, conducting the research only in female subjects creates problems in terms of 
generalization of outcomes. On the other hand, a strength of our study is the relatively large 
size of the patient sample and a consideration of subclinical ADHD symptoms that may have 
an impact on clinical features of FM. 
 
Taken together, the results of this study suggest that adult ADHD symptoms are not associated 
with the fibromyalgia impact. However, childhood ADHD symptoms are found to play a role 
in the exacerbation of symptoms in the fibromyalgia group. This effect was mediated by 
depression and anxiety symptoms. The interplay between childhood ADHD symptoms, 
vulnerability to depression and anxiety may be implicated in the development of fibromyalgia. 
Longitudinal and epidemiological studies on children and adolescents with ADHD may help to 
determine if ADHD in childhood is an actual risk factor for disease impact in fibromyalgia in 
adulthood. Our findings stress the importance of clinical evaluation of childhood and adulthood 
ADHD symptoms in patients with fibromyalgia for treatment of probable ADHD comorbidity. 
Recognizing and treating ADHD symptoms are also important for attenuating the severity of 
the disease in fibromyalgia patients. 
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Table 1. Demographic characteristics of patients with fibromyalgia and healthy controls. 
      Patients (n=64) Controls (n=58) χ2 p value 
Female 64 (100.0%) 58 (100.0%)   
Education   .106 .745 
 Primary School 39 (60.9%) 37 (63.8%)   
 High School/Bachelor/Master 25 (39.1%) 21 (36.2%)   
Work Status   .030 .863 
 Yes 33 (51.6%) 29 (50.0%)   
 No 31 (48.4%) 29 (50.0%)   
Monthly Income   .720 .698 
 Low 14 (21.9%) 13 (22.4%)   
 Middle 46 (71.9%) 39 (67.2%)   
 High 4 (6.3%) 6 (10.3%)   
Marital Status   .133 .715 
 Married 49 (76.6%) 46 (79.3%)   
 Single 15 (23.4%) 12 (20.7%)   
































Table 2. Depression, Anxiety, WURS, ASRS and ASRS subscale scores in patients with 
fibromyalgia and healthy controls. 
   Patients (n=64) 
Controls 
(n=58) F p h
2 
Depression 19.70±10.69 8.21±5.68 53.386 <0.0001 0.308 
Depression- 




Somatic 7.89±4.47 2.74±2.45 60.379 
<0.0001 
0.335 
Anxiety 23.77±13.36 8.86±6.11 60.646 <0.0001 0.336 
WURS 29.03±14.05 18.48±10.04 22.334 <0.0001 0.157 
ASRS 31.52±9.61 21.31±7.90 40.55 <0.0001 0.253 
ASRS-




deficit 16.63±5.59 10.14±4.59 48.471 
<0.0001 
0.288 
Data presented as M ± SD; WURS, Wender Utah Rating Scale; ASRS, Adult ADHD Screening 










Table 3. Breakdown of depression and anxiety scores according to severity 
    Patients (n=64) Controls (n=58) χ2 p 
Depression Group   44.293 p<.001 
 0-13 Scores 18 (28.13%) 51 (87.93%)   
 14-63 Scores 46 (71.88%) 7 (12.07%)   
Anxiety Group   43.634 p<.001 
 0-7 Scores 7 (10.94%) 26 (44.83%)   
 8-15 Scores 15 (23.44%) 23 (39.66%)   
 16-25 Scores 11 (17.19%) 9 (15.52%)   
  26-63 Scores 31 (48.44%) 0 (0.00%)    














Table 4. Correlations between measurement variables in patients with fibromyalgia and 
healthy controls. 
  1. 2. 3. 4. 5. 6. 
1. FIQ FM 1      
Controls -      
2. Depression FM .571
*** 1     
Controls - 1     
Z (p) - n/a     
3. Anxiety 
FM .562*** .581*** 1    
Controls - .541** 1    
Z (p) -- 0.314 (0.541) n/a    
4. WURS 
FM .406*** .616*** .445*** 1   
Controls - .459** .400** 1   
Z (p) - 1.197 (0.116) 
0.295 
(0.384) n/a   
5. ASRS 
FM .239 .546*** .518*** .494*** 1  
Controls - .386** .354** .572** 1  




(0.279) n/a  
6. ASRS-HA 
FM .195 .421** .452*** .489*** .852*** 1 
Controls - .320** .353** .490** .841** 1 








FM .210 .505*** .425*** .345*** .841*** .433*** 
Controls - .318* .228 .455** .812** .368** 









FIQ, Fibromyalgia Impact Questionaire; WURS, Wender Utah Rating Scale; ASRS, Adult 






















Table 5. Associations of childhood attention deficit hyperactivity disorder symptoms with 
fibromyalgia impact (model 1) and mediator role of anxiety (model 2) and depression (model 
3) in patients with fibromyalgia. 
    β t p F R² AR² 
Model 1       12.203 .16 .15 
 WURS .41 3.493 .001    
Model 2    16.171 .35 .33 
 WURS .19 1.676 .099     Anxiety  .48 4.122 .000    
Model 3    15.507 .33 .31 
 WURS .09 .652 .517     Depression .52 3.890 .000    
Dependent variable: Fibromyalgia impact      
WURS, Wender Utah Rating Scale; ASRS, Adult ADHD Screening Scale; p = p value 
(statistical significance). Statistically significant tests are reported in bold. 
 
 
 
